Eli Lilly News

TikTok star Bella Thomson also known as Bella Brave has passed away at the age of 10, New York Post reported quoting her mother Kyla Thomson. Bella Thomson has died peacefully at 4.19 pm (ET) on July 14, Kyla posted on social media. She also posted a video of joyful Bella. Bella was born in 2013 as Isabella Thomson. She suffered from multiple health issues such as Hirschsprung's disease, dwarfism, combined immunodeficiency.

U.S. health officials have approved a new Alzheimer’s drug that can modestly slow the disease

Eli Lilly has yet to get the nod from India's drug regulator for selling its blockbuster drug Tirzepatide in the country for weight loss, said the American pharmaceutical firm. «The apex drug regulator's subject expert committee (SEC) has so far given a go-ahead for its import and marketing for diabetes and not for weight loss,» Elli Lilly told ET, adding that the «obesity» indication is undergoing review by the Central Drugs Standard Control Organisation (CDSCO). The drug is marketed under the brand name Mounjaro for type 2 diabetes treatment and as Zepbound for weight loss, in the US. Mounjaro has been available in the US since 2022 while Zepbound was approved by the US FDA in November 2023. The company said it has yet to firm up the schedule for launching the drug in India.

Stocks that are trading heavily or have substantial price changes on Monday:

In this article

America’s insatiable demand for weight-loss medications is minting vast fortunes—and not just for the makers of GLP-1 drugs such as Ozempic. Shares of Hims & Hers Health, the telehealth provider better known for its trendy commercials for erectile-dysfunction medications, are up more than 150% this year. The company said last month it would start offering compounded forms of the injections that use the same active ingredients as the popular drugs Ozempic and Wegovy.

Stocks that traded heavily or had substantial price changes on Monday: RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall

Federal health advisers have endorsed a closely watched Alzheimer’s drug from Eli Lilly for people with mild dementia

In this article

A top exchange-traded fund provider is betting on the long-term popularity of GLP-1 weight loss drugs.

Hyderabad: Indian drugmaker Sun Pharmaceutical Industries posted fourth-quarter profit above estimates on Wednesday, helped by strong performance in its key U.S. and domestic markets. The company reported a consolidated net profit of ₹2,655 crore ($318.9 million) for the quarter ended March 31, compared to analysts' average estimate of ₹2,368 crore as per LSEG data.

In Britain, online pharmacies and slimming clinics are reducing prices for Wegovy and Mounjaro. This development comes months after the weight-loss drugs were launched in the country as initial supply shortages ease.

ALSO READ: US Fed bets reprice: China, Japan, South Korea and India look attractive On April 30 (Tuesday), reports on employment cost index for first quarter (Q1) and consumer confidence for April will be unveiled. On May 1 (Wednesday), data on ADP employment for April, auto sales for April, and ISM manufacturing for April will be released. On the same day, FOMC (Federal Open Market Committee) interest rate decision will be announced, followed by Fed Chair Jerome Powell’s press conference.

Biocon is building capability “to take advantage of what could be a very, very strategic peptide opportunity with GLPs at the center," Group Chief Executive Officer Peter Bains told analysts in November. The loss of exclusivity for GLPs will create a multibillion dollar market over the next 10 years and this opportunity was “very complementary" to Biocon’s current biologics business, according to Bains. In the UK, Mittal said the company will wait for the publicly-funded, National Health Service, to issue a tender to launch its liraglutide injectible.

Obesity is one of the biggest issues for health care professionals, but for those companies at the forefront of tackling it, the returns could be phenomenal.

U.S. elections and healthcare stocks have often been a losing combination. This year, with another contest looming, investors are piling in.

annual sales of obesity medicines could hit $80bn, making them one of pharma’s biggest classes of drugs. No wonder enthusiasm for the makers of these drugs, Novo Nordisk and Eli Lilly, is at fever pitch. Since the start of 2023 Novo, maker of Wegovy (and its sibling Ozempic), has seen its market capitalisation soar by 87% to $560bn, making it Europe’s most valuable company.

Investing.com — U.S. futures steadied Friday, as investors awaited the release of the key monthly jobs report for clues as to when interest rate cuts are likely to occur.

(Reuters) — S&P 500 and Nasdaq futures edged higher on Thursday ahead of more economic data and commentary from Jerome Powell after the Federal Reserve chair stuck to the script overnight by saying the central bank still expects to cut rates later this year.

By Bhanvi Satija

By Svea Herbst-Bayliss